Skip to main content
SpringerLink
Log in
Book cover

Geriatric Psychiatry pp 467–494Cite as

Neuropsychiatric Symptoms of Major or Mild Neurocognitive Disorders

  • Chapter
  • First Online:

  • 2500 Accesses

Abstract

Neuropsychiatric symptoms (NPS), or behavioral and psychological symptoms of dementia (BPSD), affect most individuals with major or mild neurocognitive disorders (NCDs), formerly termed dementia and mild cognitive impairment, at some point during the course of the illness. The near universal prevalence of NPS in NCDs has prompted the recent inclusion of non-cognitive symptoms in the core diagnostic criteria of NCDs. They are associated with a reduced quality of life and increased institutionalization, with adverse effects on both the patient and the formal and informal caregivers. Despite the prevalence of NPS, there are very few effective and safe pharmacological treatments available, partly based on the limited understanding of the underlying neurobiology of NPS. This chapter will provide a concise overview of non-cognitive symptoms of NCDs including the nature, prevalence, assessment, and management of these behaviors.

This is a preview of subscription content, log in via an institution.

References

  1. Alzheimers Disease International. Dementia statistics: numbers of people with dementia 2010; December 31, 2016. Available from: http://www.alz.co.uk/research/statistics.html.

  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders : DSM-5, vol. xliv. 5th ed. Arlington: American Psychiatric Association; 2013. p. 947.

    Book  Google Scholar 

  3. Sachs-Ericsson N, Blazer DG. The new DSM-5 diagnosis of mild neurocognitive disorder and its relation to research in mild cognitive impairment. Aging Ment Health. 2015;19(1):2–12.

    Article  PubMed  Google Scholar 

  4. Karttunen K, Karppi P, Hiltunen A, Vanhanen M, Valimaki T, Martikainen J, et al. Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer’s disease. Int J Geriatr Psychiatry. 2011;26(5):473–82.

    Article  PubMed  Google Scholar 

  5. Rabins PV, Schwartz S, Black BS, Corcoran C, Fauth E, Mielke M, et al. Predictors of progression to severe Alzheimer’s disease in an incidence sample. Alzheimers Dement. 2013;9(2):204–7.

    Article  PubMed  Google Scholar 

  6. Okura T, Plassman BL, Steffens DC, Llewellyn DJ, Potter GG, Langa KM. Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J Am Geriatr Soc. 2011;59(3):473–81.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Chan DC, Kasper JD, Black BS, Rabins PV. Presence of behavioral and psychological symptoms predicts nursing home placement in community-dwelling elders with cognitive impairment in univariate but not multivariate analysis. J Gerontol A Biol Sci Med Sci. 2003;58(6):548–54.

    Article  PubMed  Google Scholar 

  8. Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry. 2012;169(9):946–53.

    Article  PubMed  Google Scholar 

  9. Brodaty H, Draper B, Low LF. Nursing home staff attitudes towards residents with dementia: strain and satisfaction with work. J Adv Nurs. 2003;44(6):583–90.

    Article  PubMed  Google Scholar 

  10. Deutsch LH, Bylsma FW, Rovner BW, Steele C, Folstein MF. Psychosis and physical aggression in probable Alzheimer’s disease. Am J Psychiatry. 1991;148(9):1159–63.

    Article  CAS  PubMed  Google Scholar 

  11. Rovner BW, Kafonek S, Filipp L, Lucas MJ, Folstein MF. Prevalence of mental illness in a community nursing home. Am J Psychiatry. 1986;143(11):1446–9.

    Article  CAS  PubMed  Google Scholar 

  12. Malone ML, Thompson L, Goodwin JS. Aggressive behaviors among the institutionalized elderly. J Am Geriatr Soc. 1993;41(8):853–6.

    Article  CAS  PubMed  Google Scholar 

  13. Aronson MK, Post DC, Guastadisegni P. Dementia, agitation, and care in the nursing home. J Am Geriatr Soc. 1993;41(5):507–12.

    Article  CAS  PubMed  Google Scholar 

  14. Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996;8(Suppl 3):497–500.

    PubMed  Google Scholar 

  15. Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, et al. Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimers Dement. 2011;7(5):532–9.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Rosenberg PB, Mielke MM, Appleby B, Oh E, Leoutsakos JM, Lyketsos CG. Neuropsychiatric symptoms in MCI subtypes: the importance of executive dysfunction. Int J Geriatr Psychiatry. 2011;26(4):364–72.

    Article  PubMed  Google Scholar 

  17. McShane R. What are the syndromes of behavioral and psychological symptoms of dementia? Int Psychologeriatr. 2000;12:147–53.

    Article  Google Scholar 

  18. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol. 1989;44(3):M77–84.

    Article  CAS  PubMed  Google Scholar 

  19. Geda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, et al. Neuropsychiatric symptoms in Alzheimer’s disease: past progress and anticipation of the future. Alzheimers Dement. 2013;9(5):602–8.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314(12):1242–54.

    Article  CAS  PubMed  Google Scholar 

  21. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res. 1991;38(2):143–62.

    Article  CAS  PubMed  Google Scholar 

  22. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–14.

    Article  CAS  PubMed  Google Scholar 

  23. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):S10–6.

    Article  CAS  PubMed  Google Scholar 

  24. Cohen-Mansfield J. Agitation in the elderly. Adv Psychosom Med. 1989;19:101–13.

    Article  CAS  PubMed  Google Scholar 

  25. Finkel S, Rogers S. A clinical collaboration of a psychiatrist and a geriatric care manager. J Case Manag. 1992;1(2):49–52, 65.

    CAS  PubMed  Google Scholar 

  26. Reisberg B, Monteiro I, Torossian C, Auer S, Shulman MB, Ghimire S, et al. The BEHAVE-AD assessment system: a perspective, a commentary on new findings, and a historical review. Dement Geriatr Cogn Disord. 2014;38(1–2):89–146.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Auer SR, Monteiro IM, Reisberg B. The empirical behavioral pathology in Alzheimer’s disease (E-BEHAVE-AD) rating scale. Int Psychogeriatr. 1996;8(2):247–66.

    Article  CAS  PubMed  Google Scholar 

  28. Levin HS, High WM, Goethe KE, Sisson RA, Overall JE, Rhoades HM, et al. The neurobehavioural rating scale: assessment of the behavioural sequelae of head injury by the clinician. J Neurol Neurosurg Psychiatry. 1987;50(2):183–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Sultzer DL, Levin HS, Mahler ME, High WM, Cummings JL. A comparison of psychiatric symptoms in vascular dementia and Alzheimer’s disease. Am J Psychiatry. 1993;150(12):1806–12.

    Article  CAS  PubMed  Google Scholar 

  30. Sultzer DL, Levin HS, Mahler ME, High WM, Cummings JL. Assessment of cognitive, psychiatric, and behavioral disturbances in patients with dementia: the Neurobehavioral Rating Scale. J Am Geriatr Soc. 1992;40(6):549–55.

    Article  CAS  PubMed  Google Scholar 

  31. Starkstein SE, Ingram L, Garau ML, Mizrahi R. On the overlap between apathy and depression in dementia. J Neurol Neurosurg Psychiatry. 2005;76(8):1070–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol Psychiatry. 1988;23(3):271–84.

    Article  CAS  PubMed  Google Scholar 

  33. Lueken U, Seidl U, Volker L, Schweiger E, Kruse A, Schroder J. Development of a short version of the Apathy Evaluation Scale specifically adapted for demented nursing home residents. Am J Geriatr Psychiatry. 2007;15(5):376–85.

    Article  PubMed  Google Scholar 

  34. Ismail Z, Emeremni CA, Houck PR, Mazumdar S, Rosen J, Rajji TK, et al. A comparison of the E-BEHAVE-AD, NBRS, and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia. Am J Geriatr Psychiatry. 2013;21(1):78–87.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Devanand DP, Brockington CD, Moody BJ, Brown RP, Mayeux R, Endicott J, et al. Behavioral syndromes in Alzheimer’s disease. Int Psychogeriatr. 1992;4(Suppl 2):161–84.

    PubMed  Google Scholar 

  36. Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, et al. Management of behavioral problems in Alzheimer’s disease. Int Psychogeriatr. 2010;22(3):346–72.

    Article  PubMed  Google Scholar 

  37. Zhao QF, Tan L, Wang HF, Jiang T, Tan MS, Tan L, et al. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: systematic review and meta-analysis. J Affect Disord. 2016;190:264–71.

    Article  PubMed  Google Scholar 

  38. Aalten P, de Vugt ME, Lousberg R, Korten E, Jaspers N, Senden B, et al. Behavioral problems in dementia: a factor analysis of the neuropsychiatric inventory. Dement Geriatr Cogn Disord. 2003;15(2):99–105.

    Article  PubMed  Google Scholar 

  39. Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23(2):170–7.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288(12):1475–83.

    Article  PubMed  Google Scholar 

  41. Chen JC, Borson S, Scanlan JM. Stage-specific prevalence of behavioral symptoms in Alzheimer’s disease in a multi-ethnic community sample. Am J Geriatr Psychiatry. 2000;8(2):123–33.

    Article  CAS  PubMed  Google Scholar 

  42. Seitz D, Purandare N, Conn D. Prevalence of psychiatric disorders among older adults in long-term care homes: a systematic review. Int Psychogeriatr. 2010;22(7):1025–39.

    Article  PubMed  Google Scholar 

  43. Brodaty H, Draper B, Saab D, Low LF, Richards V, Paton H, et al. Psychosis, depression and behavioural disturbances in Sydney nursing home residents: prevalence and predictors. Int J Geriatr Psychiatry. 2001;16(5):504–12.

    Article  CAS  PubMed  Google Scholar 

  44. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157(5):708–14.

    Article  CAS  PubMed  Google Scholar 

  45. Srikanth S, Nagaraja AV, Ratnavalli E. Neuropsychiatric symptoms in dementia-frequency, relationship to dementia severity and comparison in Alzheimer’s disease, vascular dementia and frontotemporal dementia. J Neurol Sci. 2005;236(1–2):43–8.

    Article  CAS  PubMed  Google Scholar 

  46. Kazui H, Yoshiyama K, Kanemoto H, Suzuki Y, Sato S, Hashimoto M, et al. Differences of behavioral and psychological symptoms of dementia in disease severity in four major dementias. PLoS One. 2016;11(8):e0161092.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Chiu PY, Liu CH, Tsai CH. Neuropsychiatric manifestations in vascular cognitive impairment patients with and without dementia. Acta Neurol Taiwanica. 2007;16(2):86–91.

    Google Scholar 

  48. Staekenborg SS, Su T, van Straaten EC, Lane R, Scheltens P, Barkhof F, et al. Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease. J Neurol Neurosurg Psychiatry. 2010;81(5):547–51.

    Article  PubMed  Google Scholar 

  49. Fuh JL, Wang SJ, Cummings JL. Neuropsychiatric profiles in patients with Alzheimer’s disease and vascular dementia. J Neurol Neurosurg Psychiatry. 2005;76(10):1337–41.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Hsieh CJ, Chang CC, Lin CC. Neuropsychiatric profiles of patients with Alzheimer’s disease and vascular dementia in Taiwan. Int J Geriatr Psychiatry. 2009;24(6):570–7.

    Article  PubMed  Google Scholar 

  51. Caputo M, Monastero R, Mariani E, Santucci A, Mangialasche F, Camarda R, et al. Neuropsychiatric symptoms in 921 elderly subjects with dementia: a comparison between vascular and neurodegenerative types. Acta Psychiatr Scand. 2008;117(6):455–64.

    Article  CAS  PubMed  Google Scholar 

  52. Chiu PY, Tsai CT, Chen PK, Chen WJ, Lai TJ. Neuropsychiatric symptoms in Parkinson’s disease dementia are more similar to Alzheimer’s disease than dementia with Lewy bodies: a case-control study. PLoS One. 2016;11(4):e0153989.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  53. Noe E, Marder K, Bell KL, Jacobs DM, Manly JJ, Stern Y. Comparison of dementia with Lewy bodies to Alzheimer’s disease and Parkinson’s disease with dementia. Mov Disord. 2004;19(1):60–7.

    Article  PubMed  Google Scholar 

  54. Ballard CG, Shaw F, Lowery K, McKeith I, Kenny R. The prevalence, assessment and associations of falls in dementia with Lewy bodies and Alzheimer’s disease. Dement Geriatr Cogn Disord. 1999;10(2):97–103.

    Article  CAS  PubMed  Google Scholar 

  55. Aarsland D, Cummings JL, Larsen JP. Neuropsychiatric differences between Parkinson’s disease with dementia and Alzheimer’s disease. Int J Geriatr Psychiatry. 2001;16(2):184–91.

    Article  CAS  PubMed  Google Scholar 

  56. Grossman M. Frontotemporal dementia: a review. J Int Neuropsychol Soc. 2002;8(4):566–83.

    Article  PubMed  Google Scholar 

  57. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology. 2002;58(11):1615–21.

    Article  CAS  PubMed  Google Scholar 

  58. Banks SJ, Weintraub S. Neuropsychiatric symptoms in behavioral variant frontotemporal dementia and primary progressive aphasia. J Geriatr Psychiatry Neurol. 2008;21(2):133–41.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Mesulam MM. Primary progressive aphasia—differentiation from Alzheimer’s disease. Ann Neurol. 1987;22(4):533–4.

    Article  CAS  PubMed  Google Scholar 

  60. Barber R, Snowden JS, Craufurd D. Frontotemporal dementia and Alzheimer’s disease: retrospective differentiation using information from informants. J Neurol Neurosurg Psychiatry. 1995;59(1):61–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Levy ML, Miller BL, Cummings JL, Fairbanks LA, Craig A. Alzheimer disease and frontotemporal dementias. Behavioral distinctions. Arch Neurol. 1996;53(7):687–90.

    Article  CAS  PubMed  Google Scholar 

  62. Cohen-Mansfield J. Nonpharmacological management of behavioral problems in persons with dementia: the TREA model. Alzheim Care Q. 2000;1(4):22–34.

    Google Scholar 

  63. Hall GR, Buckwalter KC. Progressively lowered stress threshold: a conceptual model for care of adults with Alzheimer’s disease. Arch Psychiatr Nurs. 1987;1(6):399–406.

    CAS  PubMed  Google Scholar 

  64. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry. 2001;9(4):361–81.

    Article  CAS  PubMed  Google Scholar 

  65. Kitwood T. Person and process in dementia. Int J Geriatr Psychiatry. 1993;8:541–5.

    Article  Google Scholar 

  66. Casanova MF, Starkstein SE, Jellinger KA. Clinicopathological correlates of behavioral and psychological symptoms of dementia. Acta Neuropathol. 2011;122(2):117–35.

    Article  PubMed  Google Scholar 

  67. Halliday GM, McCann HL, Pamphlett R, Brooks WS, Creasey H, McCusker E, et al. Brain stem serotonin-synthesizing neurons in Alzheimer’s disease: a clinicopathological correlation. Acta Neuropathol. 1992;84(6):638–50.

    Article  CAS  PubMed  Google Scholar 

  68. Mann DM, Yates PO. Serotonin nerve cells in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 1983;46(1):96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Sukonick DL, Pollock BG, Sweet RA, Mulsant BH, Rosen J, Klunk WE, et al. The 5-HTTPRS/L polymorphism and aggressive behavior in Alzheimer disease. Arch Neurol. 2001;58(9):1425–8.

    Article  CAS  PubMed  Google Scholar 

  70. Sweet RA, Pollock BG, Sukonick DL, Mulsant BH, Rosen J, Klunk WE, et al. The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease. Int Psychogeriatr. 2001;13(4):401–9.

    Article  CAS  PubMed  Google Scholar 

  71. Pritchard AL, Pritchard CW, Bentham P, Lendon CL. Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients. Dement Geriatr Cogn Disord. 2007;24(3):201–6.

    Article  CAS  PubMed  Google Scholar 

  72. Assal F, Alarcon M, Solomon EC, Masterman D, Geschwind DH, Cummings JL. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch Neurol. 2004;61(8):1249–53.

    Article  PubMed  Google Scholar 

  73. Rocchi A, Micheli D, Ceravolo R, Manca ML, Tognoni G, Siciliano G, et al. Serotoninergic polymorphisms (5-HTTLPR and 5-HT2A): association studies with psychosis in Alzheimer disease. Genet Test. 2003;7(4):309–14.

    Article  CAS  PubMed  Google Scholar 

  74. Ueki A, Ueno H, Sato N, Shinjo H, Morita Y. Serotonin transporter gene polymorphism and BPSD in mild Alzheimer’s disease. J Alzheimers Dis. 2007;12(3):245–53.

    Article  CAS  PubMed  Google Scholar 

  75. Holmes C, Arranz M, Collier D, Powell J, Lovestone S. Depression in Alzheimer’s disease: the effect of serotonin receptor gene variation. Am J Med Genet B Neuropsychiatr Genet. 2003;119B(1):40–3.

    Article  PubMed  Google Scholar 

  76. Micheli D, Bonvicini C, Rocchi A, Ceravolo R, Mancuso M, Tognoni G, et al. No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease. J Alzheimers Dis. 2006;10(4):371–8.

    Article  CAS  PubMed  Google Scholar 

  77. Lai MK, Tsang SW, Francis PT, Esiri MM, Keene J, Hope T, et al. Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Res. 2003;974(1–2):82–7.

    Article  CAS  PubMed  Google Scholar 

  78. Garcia-Alloza M, Hirst WD, Chen CP, Lasheras B, Francis PT, Ramirez MJ. Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer’s disease. Neuropsychopharmacology. 2004;29(2):410–6.

    Article  CAS  PubMed  Google Scholar 

  79. Lanctot KL, Herrmann N, Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci. 2001;13(1):5–21.

    Article  CAS  PubMed  Google Scholar 

  80. Lanctot KL, Herrmann N, Eryavec G, van Reekum R, Reed K, Naranjo CA. Central serotonergic activity is related to the aggressive behaviors of Alzheimer’s disease. Neuropsychopharmacology. 2002;27(4):646–54.

    CAS  PubMed  Google Scholar 

  81. Lanctot KL, Herrmann N, van Reekum R, Eryavec G, Naranjo CA. Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer’s disease. Int J Geriatr Psychiatry. 2002;17(6):531–41.

    Article  PubMed  Google Scholar 

  82. Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, Chen CP, Francis PT, Lasheras B, et al. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer’s disease. Neuropsychologia. 2005;43(3):442–9.

    Article  CAS  PubMed  Google Scholar 

  83. Herrmann N, Lanctot KL, Khan LR. The role of norepinephrine in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci. 2004;16(3):261–76.

    Article  CAS  PubMed  Google Scholar 

  84. Matthews KL, Chen CP, Esiri MM, Keene J, Minger SL, Francis PT. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol Psychiatry. 2002;51(5):407–16.

    Article  CAS  PubMed  Google Scholar 

  85. Engelborghs S, Vloeberghs E, Le Bastard N, Van Buggenhout M, Marien P, Somers N, et al. The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. Neurochem Int. 2008;52(6):1052–60.

    Article  CAS  PubMed  Google Scholar 

  86. Tanaka Y, Meguro K, Yamaguchi S, Ishii H, Watanuki S, Funaki Y, et al. Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer’s disease. Ann Nucl Med. 2003;17(7):567–73.

    Article  PubMed  Google Scholar 

  87. Lanctot KL, Herrmann N, Rothenburg L, Eryavec G. Behavioral correlates of GABAergic disruption in Alzheimer’s disease. Int Psychogeriatr. 2007;19(1):151–8.

    Article  PubMed  Google Scholar 

  88. Garcia-Alloza M, Tsang SW, Gil-Bea FJ, Francis PT, Lai MK, Marcos B, et al. Involvement of the GABAergic system in depressive symptoms of Alzheimer’s disease. Neurobiol Aging. 2006;27(8):1110–7.

    Article  CAS  PubMed  Google Scholar 

  89. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, et al. Ways toward an early diagnosis in Alzheimer’s disease: the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 2005;1(1):55–66.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2013;9(5):e111–94.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Fischer CE, Ting WK, Millikin CP, Ismail Z, Schweizer TA, Alzheimer Disease Neuroimaging I. Gray matter atrophy in patients with mild cognitive impairment/Alzheimer’s disease over the course of developing delusions. Int J Geriatr Psychiatry. 2016;31(1):76–82.

    Article  PubMed  Google Scholar 

  92. Ting WK, Fischer CE, Millikin CP, Ismail Z, Chow TW, Schweizer TA. Grey matter atrophy in mild cognitive impairment/early Alzheimer disease associated with delusions: a voxel-based morphometry study. Curr Alzheimer Res. 2015;12(2):165–72.

    Article  CAS  PubMed  Google Scholar 

  93. Rafii MS, Taylor CS, Kim HT, Desikan RS, Fleisher AS, Katibian D, et al. Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2014;29(2):159–65.

    Article  PubMed  Google Scholar 

  94. Bruen PD, McGeown WJ, Shanks MF, Venneri A. Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer’s disease. Brain. 2008;131(Pt 9):2455–63.

    Article  PubMed  Google Scholar 

  95. Ismail Z, Nguyen MQ, Fischer CE, Schweizer TA, Mulsant BH. Neuroimaging of delusions in Alzheimer’s disease. Psychiatry Res. 2012;202(2):89–95.

    Article  PubMed  Google Scholar 

  96. Blanc F, Noblet V, Philippi N, Cretin B, Foucher J, Armspach JP, et al. Right anterior insula: core region of hallucinations in cognitive neurodegenerative diseases. PLoS One. 2014;9(12):e114774.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  97. Donovan NJ, Wadsworth LP, Lorius N, Locascio JJ, Rentz DM, Johnson KA, et al. Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer disease spectrum. Am J Geriatr Psychiatry. 2014;22(11):1168–79.

    Article  PubMed  Google Scholar 

  98. Balthazar ML, Pereira FR, Lopes TM, da Silva EL, Coan AC, Campos BM, et al. Neuropsychiatric symptoms in Alzheimer’s disease are related to functional connectivity alterations in the salience network. Hum Brain Mapp. 2014;35(4):1237–46.

    Article  PubMed  Google Scholar 

  99. Rosenberg PB, Nowrangi MA, Lyketsos CG. Neuropsychiatric symptoms in Alzheimer’s disease: what might be associated brain circuits? Mol Asp Med. 2015;43-44:25–37.

    Article  Google Scholar 

  100. Levy-Cooperman N, Burhan AM, Rafi-Tari S, Kusano M, Ramirez J, Caldwell C, et al. Frontal lobe hypoperfusion and depressive symptoms in Alzheimer disease. J Psychiatry Neurosci. 2008;33(3):218–26.

    PubMed  PubMed Central  Google Scholar 

  101. Kataoka K, Hashimoto H, Kawabe J, Higashiyama S, Akiyama H, Shimada A, et al. Frontal hypoperfusion in depressed patients with dementia of Alzheimer type demonstrated on 3DSRT. Psychiatry Clin Neurosci. 2010;64(3):293–8.

    Article  PubMed  Google Scholar 

  102. Akiyama H, Hashimoto H, Kawabe J, Higashiyama S, Kai T, Kataoka K, et al. The relationship between depressive symptoms and prefrontal hypoperfusion demonstrated by eZIS in patients with DAT. Neurosci Lett. 2008;441(3):328–31.

    Article  CAS  PubMed  Google Scholar 

  103. Terada S, Oshima E, Sato S, Ikeda C, Nagao S, Hayashi S, et al. Depressive symptoms and regional cerebral blood flow in Alzheimer’s disease. Psychiatry Res. 2014;221(1):86–91.

    Article  PubMed  Google Scholar 

  104. Holthoff VA, Beuthien-Baumann B, Kalbe E, Ludecke S, Lenz O, Zundorf G, et al. Regional cerebral metabolism in early Alzheimer’s disease with clinically significant apathy or depression. Biol Psychiatry. 2005;57(4):412–21.

    Article  CAS  PubMed  Google Scholar 

  105. Kim HJ, Ye BS, Yoon CW, Cho H, Noh Y, Kim GH, et al. Effects of APOE epsilon4 on brain amyloid, lacunar infarcts, and white matter lesions: a study among patients with subcortical vascular cognitive impairment. Neurobiol Aging. 2013;34(11):2482–7.

    Article  CAS  PubMed  Google Scholar 

  106. Murray PS, Kirkwood CM, Gray MC, Fish KN, Ikonomovic MD, Hamilton RL, et al. Hyperphosphorylated tau is elevated in Alzheimer’s disease with psychosis. J Alzheimers Dis. 2014;39(4):759–73.

    CAS  PubMed  PubMed Central  Google Scholar 

  107. Burhan AM, Marlatt NM, Palaniyappan L, Anazodo UC, Prato FS. Role of hybrid brain imaging in neuropsychiatric disorders. Diagnostics (Basel). 2015;5(4):577–614.

    Article  CAS  Google Scholar 

  108. Odenheimer G, Borson S, Sanders AE, Swain-Eng RJ, Kyomen HH, Tierney S, et al. Quality improvement in neurology: dementia management quality measures. Neurology. 2013;81(17):1545–9.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Cohen-Mansfield J, Libin A, Marx MS. Nonpharmacological treatment of agitation: a controlled trial of systematic individualized intervention. J Gerontol A Biol Sci Med Sci. 2007;62(8):908–16.

    Article  PubMed  Google Scholar 

  110. Kales HC, Gitlin LN, Lyketsos CG, Detroit Expert Panel on A, Management of Neuropsychiatric Symptoms of D. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762–9.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Hogan DB, Bailey P, Black S, Carswell A, Chertkow H, Clarke B, et al. Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. CMAJ. 2008;179(8):787–93.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013;3:CD007726.

    Google Scholar 

  114. Steinberg M, Tschanz JT, Corcoran C, Steffens DC, Norton MC, Lyketsos CG, et al. The persistence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2004;19(1):19–26.

    Article  PubMed  Google Scholar 

  115. Aalten P, de Vugt ME, Jaspers N, Jolles J, Verhey FR. The course of neuropsychiatric symptoms in dementia. Part I: findings from the two-year longitudinal Maasbed study. Int J Geriatr Psychiatry. 2005;20(6):523–30.

    Article  PubMed  Google Scholar 

  116. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990;113(12):941–8.

    Article  CAS  PubMed  Google Scholar 

  117. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD003476.

    Google Scholar 

  118. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–43.

    Article  CAS  PubMed  Google Scholar 

  119. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335–41.

    Article  CAS  PubMed  Google Scholar 

  120. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64(2):134–43.

    Article  CAS  PubMed  Google Scholar 

  121. Seitz DP, Brisbin S, Herrmann N, Rapoport MJ, Wilson K, Gill SS, et al. Efficacy and feasibility of nonpharmacological interventions for neuropsychiatric symptoms of dementia in long term care: a systematic review. J Am Med Dir Assoc. 2012;13(6):503–6 e2.

    Article  PubMed  Google Scholar 

  122. Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA. 2012;308(19):2020–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Scherder EJ, Bogen T, Eggermont LH, Hamers JP, Swaab DF. The more physical inactivity, the more agitation in dementia. Int Psychogeriatr. 2010;22(8):1203–8.

    Article  PubMed  Google Scholar 

  124. Telenius EW, Engedal K, Bergland A. Long-term effects of a 12 weeks high-intensity functional exercise program on physical function and mental health in nursing home residents with dementia: a single blinded randomized controlled trial. BMC Geriatr. 2015;15:158.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  125. Lowery D, Cerga-Pashoja A, Iliffe S, Thune-Boyle I, Griffin M, Lee J, et al. The effect of exercise on behavioural and psychological symptoms of dementia: the EVIDEM-E randomised controlled clinical trial. Int J Geriatr Psychiatry. 2014;29(8):819–27.

    Article  PubMed  Google Scholar 

  126. Barreto Pde S, Demougeot L, Pillard F, Lapeyre-Mestre M, Rolland Y. Exercise training for managing behavioral and psychological symptoms in people with dementia: a systematic review and meta-analysis. Ageing Res Rev. 2015;24(Pt B):274–85.

    Article  PubMed  Google Scholar 

  127. Brett L, Traynor V, Stapley P. Effects of physical exercise on health and well-being of individuals living with a dementia in nursing homes: a systematic review. J Am Med Dir Assoc. 2016;17(2):104–16.

    Article  PubMed  Google Scholar 

  128. Shih YH, Pai MC, Huang YC, Wang JJ. Sundown syndrome, sleep quality, and walking among community-dwelling people with Alzheimer disease. J Am Med Dir Assoc. 2017;18:396.

    Article  PubMed  Google Scholar 

  129. Oppikofer S, Geschwindner H. Nursing interventions in cases of agitation and dementia. Dementia (London). 2014;13(3):306–17.

    Article  Google Scholar 

  130. Douglas S, James I, Ballard C. Non-parmacological interventions in dementia. J Contin Prof Dev. 2004;10:171–7.

    Google Scholar 

  131. Malara A, De Biase GA, Bettarini F, Ceravolo F, Di Cello S, Garo M, et al. Pain assessment in elderly with behavioral and psychological symptoms of dementia. J Alzheimers Dis. 2016;50(4):1217–25.

    Article  PubMed  PubMed Central  Google Scholar 

  132. Habiger TF, Flo E, Achterberg WP, Husebo BS. The interactive relationship between pain, psychosis, and agitation in people with dementia: results from a cluster-randomised clinical trial. Behav Neurol. 2016;2016:7036415.

    Article  PubMed  PubMed Central  Google Scholar 

  133. Zwakhalen SM, Hamers JP, Abu-Saad HH, Berger MP. Pain in elderly people with severe dementia: a systematic review of behavioural pain assessment tools. BMC Geriatr. 2006;6:3.

    Article  PubMed  PubMed Central  Google Scholar 

  134. Gitlin LN, Winter L, Dennis MP, Hodgson N, Hauck WW. Targeting and managing behavioral symptoms in individuals with dementia: a randomized trial of a nonpharmacological intervention. J Am Geriatr Soc. 2010;58(8):1465–74.

    Article  PubMed  PubMed Central  Google Scholar 

  135. Belle SH, Burgio L, Burns R, Coon D, Czaja SJ, Gallagher-Thompson D, et al. Enhancing the quality of life of dementia caregivers from different ethnic or racial groups: a randomized, controlled trial. Ann Intern Med. 2006;145(10):727–38.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990;38(5):553–63.

    Article  CAS  PubMed  Google Scholar 

  137. Yury CA, Fisher JE. Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia. Psychother Psychosom. 2007;76(4):213–8.

    Article  PubMed  Google Scholar 

  138. Ma H, Huang Y, Cong Z, Wang Y, Jiang W, Gao S, et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2014;42(3):915–37.

    PubMed  Google Scholar 

  139. Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer’s disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007;22(5):475–84.

    Article  PubMed  Google Scholar 

  140. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191–210.

    Article  PubMed  Google Scholar 

  141. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355(15):1525–38.

    Article  CAS  PubMed  Google Scholar 

  142. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596–608.

    Article  CAS  PubMed  Google Scholar 

  143. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev. 2002;(2):CD002852.

    Google Scholar 

  144. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601.

    Article  Google Scholar 

  145. Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775–86.

    Article  PubMed  Google Scholar 

  146. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627–32.

    Article  PubMed  PubMed Central  Google Scholar 

  147. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012;169(1):71–9.

    Article  PubMed  Google Scholar 

  148. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8(2):151–7.

    Article  CAS  PubMed  Google Scholar 

  149. Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;(2):CD008191.

    Google Scholar 

  150. Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. Schneider LS, Frangakis C, Drye LT, Devanand DP, Marano CM, Mintzer J, et al. Heterogeneity of treatment response to citalopram for patients with Alzheimer’s disease with aggression or agitation: the CitAD randomized clinical trial. Am J Psychiatry. 2016;173(5):465–72.

    Article  PubMed  Google Scholar 

  152. Leonpacher AK, Peters ME, Drye LT, Makino KM, Newell JA, Devanand DP, et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer’s dementia: evidence from the CitAD study. Am J Psychiatry. 2016;173(5):473–80.

    Article  PubMed  Google Scholar 

  153. Weintraub D, Drye LT, Porsteinsson AP, Rosenberg PB, Pollock BG, Devanand DP, et al. Time to response to citalopram treatment for agitation in Alzheimer disease. Am J Geriatr Psychiatry. 2015;23(11):1127–33.

    Article  PubMed  PubMed Central  Google Scholar 

  154. Newell J, Yesavage JA, Taylor JL, Kraemer HC, Munro CA, Friedman L, et al. Sedation mediates part of Citalopram’s effect on agitation in Alzheimer’s disease. J Psychiatr Res. 2016;74:17–21.

    Article  PubMed  Google Scholar 

  155. Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, Marano C, et al. Citalopram for agitation in Alzheimer’s disease: design and methods. Alzheimers Dement. 2012;8(2):121–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  156. Rosenberg PB, Drye LT, Porsteinsson AP, Pollock BG, Devanand DP, Frangakis C, et al. Change in agitation in Alzheimer’s disease in the placebo arm of a nine-week controlled trial. Int Psychogeriatr. 2015;27(12):2059–67.

    Article  PubMed  PubMed Central  Google Scholar 

  157. Konovalov S, Muralee S, Tampi RR. Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. Int Psychogeriatr. 2008;20(2):293–308.

    Article  PubMed  Google Scholar 

  158. Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155(1):54–61.

    Article  CAS  PubMed  Google Scholar 

  159. Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry. 2001;9(4):400–5.

    Article  CAS  PubMed  Google Scholar 

  160. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289(2):210–6.

    Article  CAS  PubMed  Google Scholar 

  161. Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, et al. Donepezil for the treatment of agitation in Alzheimer’s disease. N Engl J Med. 2007;357(14):1382–92.

    Article  CAS  PubMed  Google Scholar 

  162. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012;(3):CD006504.

    Google Scholar 

  163. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008;23(5):537–45.

    Article  CAS  PubMed  Google Scholar 

  164. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69(3):341–8.

    Article  CAS  PubMed  Google Scholar 

  165. Fox C, Crugel M, Maidment I, Auestad BH, Coulton S, Treloar A, et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double-blind placebo controlled trial. PLoS One. 2012;7(5):e35185.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  166. Peisah C, Chan DK, McKay R, Kurrle SE, Reutens SG. Practical guidelines for the acute emergency sedation of the severely agitated older patient. Intern Med J. 2011;41(9):651–7.

    Article  CAS  PubMed  Google Scholar 

  167. Wang LY, Shofer JB, Rohde K, Hart KL, Hoff DJ, McFall YH, et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry. 2009;17(9):744–51.

    Article  PubMed  PubMed Central  Google Scholar 

  168. Vasudev A, Shariff SZ, Liu K, Burhan AM, Herrmann N, Leonard S, et al. Trends in psychotropic dispensing among older adults with dementia living in long-term care facilities: 2004–2013. Am J Geriatr Psychiatry. 2015;23(12):1259–69.

    Article  PubMed  Google Scholar 

  169. Podsiadlo D, Richardson S. The timed “up & go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–8.

    Article  CAS  PubMed  Google Scholar 

  170. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.

    Article  CAS  PubMed  Google Scholar 

  171. Honore PM, Spapen HD. Cefepime-induced neurotoxicity in critically ill patients undergoing continuous renal replacement therapy: beware of dose reduction! Crit Care. 2015;19:455.

    Article  PubMed  PubMed Central  Google Scholar 

  172. Pedroso JL, Nakama GY, Carneiro Filho M, Barsottini OG. Delirium, psychosis, and visual hallucinations induced by pregabalin. Arq Neuropsiquiatr. 2012;70(12):960–1.

    Article  PubMed  Google Scholar 

  173. Vasudev A, Macritchie K, Vasudev K, Watson S, Geddes J, Young AH. Oxcarbazepine for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev. 2017;(12):CD004857.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Parkwood Institute-Mental Health/Western University, London, ON, Canada

    Amer M. Burhan MBChB, MSc

  2. Division of General Medicine, University of California Davis Medical Center, Sacramento, CA, USA

    Calvin H. Hirsch

  3. Department of Psychiatry, St. Joseph’s Health Care London, Parkwood Institute, London, ON, Canada

    Nicole E. Marlatt

Authors
  1. Amer M. Burhan MBChB, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Calvin H. Hirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicole E. Marlatt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amer M. Burhan MBChB, MSc .

Editor information

Editors and Affiliations

  1. Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada

    Ana Hategan

  2. Baylor Scott and White Department of Psychiatry, Texas A&M University College of Medicine, Temple, Texas, USA

    James A. Bourgeois

  3. Division of General Medicine, University of California Davis Medical Center, Sacramento, California, USA

    Calvin H. Hirsch

  4. Department of Psychiatry and Behavioral Sciences, University of California Davis Medical Center, Sacramento, California, USA

    Caroline Giroux

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Burhan, A.M., Hirsch, C.H., Marlatt, N.E. (2018). Neuropsychiatric Symptoms of Major or Mild Neurocognitive Disorders. In: Hategan, A., Bourgeois, J., Hirsch, C., Giroux, C. (eds) Geriatric Psychiatry. Springer, Cham. https://doi.org/10.1007/978-3-319-67555-8_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-67555-8_22

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-67554-1

  • Online ISBN: 978-3-319-67555-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation